⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714168 | 0.79 | — | — | |
| SCHEMBL1920152 | 0.79 | — | — | |
| SCHEMBL31513478 | 0.75 | — | — | |
| SCHEMBL7023123 | 0.75 | — | — | |
| SCHEMBL157175 | 0.75 | — | — | |
| SCHEMBL321812 | 0.72 | — | — | |
| SCHEMBL1968058 | 0.72 | — | — | |
| SCHEMBL6203814 | 0.72 | — | — | |
| SCHEMBL30477974 | 0.72 | — | — | |
| SCHEMBL4352639 | 0.72 | PARP1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428411-B2 | Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-09-30 | — | — | US | disclosed |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-12410159-B2 | Preparation of oxindole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| US-20250122226-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2025-04-17 | — | — | US | disclosed |
| US-12252493-B2 | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer | Mirati Therapeutics, Inc. (US) | 2025-03-18 | — | — | US | disclosed |
| WO-2025043191-A1 | PRC2 INHIBITORS FOR USE IN TREATING SICKLE CELL DISEASE | ORIC PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| WO-2013162072-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-10-31 | — | — | WO | disclosed |
| EP-2655370-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2013-10-30 | — | — | EP | disclosed |
| CN-103201262-A | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS INC | 2013-07-10 | — | — | CN | disclosed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| EP-2606031-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | Amira Pharmaceuticals, Inc. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012149413-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012087519-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087519-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012024620-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | WO | disclosed |